Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216482 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
A Phase 3 study of Hyperlipidemia, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 975
- Enrollment target
- 20
- Study locations
NCT07216482: Recruiting Phase 3 study of Hyperlipidemia, sponsored by Merck Sharp & Dohme.
NCT07216482 is a Phase 3 study of Hyperlipidemia that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 975 participants, above the 380-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (157% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216482, a Phase 3 study of Hyperlipidemia, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 975 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.
Primary Outcome
Blood samples will be collected at baseline and at Week 8 to assess mean percent change in LDL-C between participants treated with enlicitide and rosuvastatin versus placebo.
Conditions Studied
Interventions
- DRUG Rosuvastatin
- DRUG Enlicitide
- DRUG Placebo for Enlicitide
- DRUG Placebo for Rosuvastatin
Study Locations (20)
Florida
- Alliance for Multispecialty Research, LLC ( Site 0040) - Fort Myers
- Soffer Health Institute ( Site 0046) - Hollywood
- East Coast Institute for Research ( Site 0041) - Lake City
- Inpatient Research Clinic ( Site 0017) - Miami Lakes
- Clinical Research Trials of Florida ( Site 0001) - Tampa
- Clinical Site Partners LLC, dba CSP Orlando ( Site 0014) - Winter Park
Alabama
- Central Research Associates ( Site 0009) - Birmingham
- G&L Research ( Site 0024) - Foley
Arizona
- Synexus Clinical Research US, Inc. - Phoenix Central ( Site 0030) - Phoenix
- Alliance for Multispecialty Research LLC ( Site 0049) - Tempe
California
- Chemidox Clinical Trials ( Site 0008) - Lancaster
- Clinical Trials Research ( Site 0036) - Sacramento
Illinois
- Trialmed ( Site 0026) - Chicago
- Great Lakes Clinical Trials - Ravenswood ( Site 0018) - Chicago
Kansas
- Alliance for Multispecialty Research, LLC ( Site 0048) - Newton
- Cotton O'Neil Clinical Research Center ( Site 0006) - Topeka
Colorado
- Legacy Clinical Trials ( Site 0044) - Colorado Springs
Indiana
- Midwest Institute For Clinical Research ( Site 0033) - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2025-11-11 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 3 |
What NCT07216482 shows while recruiting
NCT07216482 is an interventional study that assigns participants to a tested intervention. The registered 975 participants enrollment target is mid-sized for trials with a published cap, above the 380-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (157% higher).
The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 4 interventions - of which Rosuvastatin is the first listed.
NCT07216482 names 20 study sites across 10 states, led by Florida, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT07216482 about?
NCT07216482 is a clinical study titled "A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)". Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this stu...
What is the current status of trial NCT07216482?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 975 participants. The study started on 2025-11-11. Estimated completion is 2027-03-01.
What conditions does trial NCT07216482 study?
This clinical trial studies the following conditions: Hyperlipidemia.
What interventions are being tested in trial NCT07216482?
The interventions under investigation include: Rosuvastatin (DRUG), Enlicitide (DRUG), Placebo for Enlicitide (DRUG), Placebo for Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT07216482?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216482 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperlipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07216482's enrollment target sits among peer trials
975 5th of 35 higher than 31 of 35 other Hyperlipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperlipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Low Carbohydrate Diet Compared to Calorie and Fat Restricted Diet in Patients With Obesity and Type II Diabetes
COMPLETED · Phase 3
-
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
COMPLETED · Phase 3
-
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
COMPLETED · Phase 3
-
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
COMPLETED · Phase 3
-
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI